3sbio Inc operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares 3sbio Inc with three other
companies in this sector in CHINA :
Luoxin Pharmaceuticals Group Stock Co Ltd
sales of 6.10 billion Chinese Renmimbi [US$944.69 million]
of which 63%
was Pharmaceutical industry),
Guizhou Xinbang Pharmaceutical Company Limited
(5.85 billion Chinese Renmimbi [US$905.90 million]
of which 83%
was Pharmaceutical industry), and
Zhejiang Conba Pharmaceutical Co., Ltd.
(5.91 billion Chinese Renmimbi [US$915.49 million]
of which 96%
was Jiangsu, Zhejiang and Shanghai Branch).
3sbio Inc reported sales of 5.59 billion Chinese Renmimbi (US$865.92 million)
December of 2020.
increase of 5.1%
versus 2019, when the company's sales were 5.32 billion Chinese Renmimbi.
Sales at 3sbio Inc have increased during each of the previous five years
(and since 2015, sales have increased a total of 234%).
Sales of Biopharmaceuticals saw an increase
4.9% in 2020, from
5.29 billion Chinese Renmimbi to 5.55 billion Chinese Renmimbi.
Not all segments of 3sbio Inc experienced an increase in sales in 2020:
sales of Technical Service fell 59.7% to 10.35 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).